Identification of an HLA‐A*24:02‐restricted α ‐fetoprotein signal peptide‐derived antigen and its specific T‐cell receptor for T‐cell immunotherapy

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunotherapy in hepatocellular carcinoma

(2019) Luigi Buonaguro et al.   Annals of Hepatology

Immune cell therapy for hepatocellular carcinoma

(2019) Eishiro Mizukoshi et al.   Journal of Hematology & Oncology

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

(2019) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities

(2019) Chen Lu et al.   Molecular Cancer

Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy

(2018) Wei Zhu et al.   HEPATOLOGY

Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs

(2018) Helena M. Bijen et al.   MOLECULAR THERAPY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tuning T cell receptor affinity to optimize clinical risk-benefit when targeting α-fetoprotein-positive liver cancer

(2018) Roslin Y. Docta et al.   HEPATOLOGY

Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein−Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma

(2017) Hidetoshi Nakagawa et al.   GASTROENTEROLOGY

Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors

(2017) Huajun Zhang et al.   JOURNAL OF GENERAL VIROLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

(2017) et al.   JAMA Oncology

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

(2016) Hong Liu et al.   CLINICAL CANCER RESEARCH

Mass spectrometry-based antigen discovery for cancer immunotherapy

(2016) Michal Bassani-Sternberg et al.   CURRENT OPINION IN IMMUNOLOGY

T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells: Table 1.

(2016) Hiroaki Ikeda   INTERNATIONAL IMMUNOLOGY

Effect of HCV clearance with direct-acting antiviral agents on HCC

(2016) Josep M. Llovet et al.   Nature Reviews Gastroenterology & Hepatology

NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets

(2016) Morten Nielsen et al.   Genome Medicine

Cancer Neoantigens and Applications for Immunotherapy

(2015) A. Desrichard et al.   CLINICAL CANCER RESEARCH

TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity

(2015) Jennifer D Stone et al.   CURRENT OPINION IN IMMUNOLOGY

Distribution of HLA haplotypes across Japanese Archipelago: similarity, difference and admixture

(2015) Hirofumi Nakaoka et al.   JOURNAL OF HUMAN GENETICS

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens

(2015) Michael Hebeisen et al.   Frontiers in Immunology

Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome

(2015) Cláudia C. Oliveira et al.   Frontiers in Immunology

The use of signal peptide domains as vaccine candidates

(2014) Riva Kovjazin et al.   Human Vaccines & Immunotherapeutics

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

(2013) S. Zhong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells

(2013) B. J. Cameron et al.   Science Translational Medicine

Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies

(2012) Milos Aleksic et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells

(2009) Yuqing Shen et al.   MOLECULAR IMMUNOLOGY